Exploring Breast Cancer Systemic Drug Therapy Patterns in Real-World Data

• DOI: 10.1200/cci.23.00061
• Publication Date: 2023-10-18T19:59:47Z
• Authors: Julia O'Rourke; Jeff Warnick; John Doole; Luc De Keyser; Zuzanna Drebert; Olivia Wan; Courtney N. Thompson; Jack W. London; Karen Fairchild; Matvey B. Palchuk
• Keywords: Carboplatin

To explore medications and their administration patterns in real-world patients with breast cancer.A retrospective study was performed using TriNetX, a federated network of deidentified, Health Insurance Portability Accountability Act-compliant data from 21 health care organizations across North America. Patients diagnosed cancer between January 1, 2013, May 31, 2022, were included. We investigated rule-based unsupervised learning algorithm to extract patterns. group similar patterns, we used three features k-means clustering: total number administrations, median days standard deviation the administrations. explored first lines therapy for classified into six groups on basis stage at diagnosis (early as stages I-III v late IV) sensitivity tumor's receptors targeted therapies: hormone receptor-positive/human epidermal growth factor 2-negative (HR+/ERBB2-), ERBB2-positive (ERBB2+/HR±), or triple-negative (TN; HR-/ERBB2-). add credence derived regimens, compared them National Comprehensive Cancer Network (NCCN): Breast (version 2.2023) recommendations.In early-stage HR+/ERBB2- TN groups, most common regimens (1) cyclophosphamide docetaxel, administered once every 3 weeks cycles (2) doxorubicin, 2 four cycles, followed by paclitaxel week 12 cycles. In ERBB2+/HR± group, carboplatin docetaxel without pertuzumab trastuzumab (for more cycles). Medications commonly our set (7,798 patients) agreed recommendations NCCN terms (regimens), administrations (cycles), (cycle length).Although there is general agreement Guidelines, medication exhibit variability